share_log

全球首个IgA肾病对因治疗药物耐赋康首张处方顺利开出 每瓶定价仅为美国的十分之一

The world's first IgA nephropathy treatment was successfully prescribed for resistance to the drug fukang, and the price per bottle was only one-tenth of the US

Zhitong Finance ·  May 15 19:40

With the successful dispensing of Nifukang's first prescription, the cost of its treatment attracted widespread attention in the market.

The Zhitong Finance App learned that with the successful issuance of Nifukang's first prescription, its treatment costs have attracted widespread attention in the market. According to an authoritative source, Nifukang's pricing strategy is very friendly. You can get one bottle for only 18,600 yuan, and if you buy four bottles, you will also get an additional bottle, reducing the actual price paid for each bottle to 14,900 yuan, thus significantly increasing its cost performance advantage. What is particularly remarkable is that each treatment cycle requires only 9.5 bottles of Nafucan, and an additional 2 bottles will be received during this period, which undoubtedly brings more real benefits and benefits to patients.

At the same time, compared to the high price of 100,000 yuan/bottle in the US market, Nifukang's domestic pricing can be called “affordable”, which is only equivalent to a 15% discount, fully demonstrating its strong competitiveness in terms of price. Behind this competitiveness is Nifukang's outstanding performance in treating IgA nephropathy. According to reports, Nifukang can effectively delay the time for patients to enter the dialysis or kidney transplant stage, and its remarkable curative effects can even benefit patients for as long as 12.8 years. Taking Chinese patients as an example, their disease progressed faster. The phase III clinical study showed that in two years, EGFR in the control group that only used RAS inhibitors decreased by 21 ml/min, while in the treatment group that used only defucan decreased by 7 ml/min, a decrease of 66%, so the sooner you use Tolerant Health, the more remaining kidney function was saved, and the risk of progression to kidney failure was lower.

Also, considering the high cost of dialysis treatment, that is, at least 100,000 yuan per year, the cost of the entire dialysis treatment process will be as high as 1 million yuan in the long run. In contrast, choosing to use Nifukang can not only obtain more significant treatment results, but also reduce the financial burden on patients and their families to a large extent. Therefore, the launch of Nifukang undoubtedly provides patients with an efficient and economical treatment option, achieving a perfect combination of medical effects and economic benefits.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment